|
3-(4’aminoisoindoline-1′-one)-1-piperidine-2,6-dione |
|---|---|
| Trade Name | Revlimid |
| Orphan Indication | Incontinentia pigmenti |
| EU Market Approval | EU |
| EU Designation Date | 2003-12-12 00:00:00 |
| Sponsor | Celgene Europe Limited |
Related Access Program
National Taiwan University Hospital – Hyperlipidemia
Fudan University – Triple Negative Breast Cancer
Hospital for Special Surgery, New York – Arthroplasty of the PIP Joint
Zimmer Biomet – Peripheral Vascular Diseases
Zimmer Biomet – Peripheral Arterial Disease
Kristin Fiorino – Refractory Gastroesophageal Reflux Disease With Upper Gastrointestinal (GI) Symptoms, Gastroparesis, and Chronic Constipation
Dana-Farber Cancer Institute – Multiple Myeloma in Relapse
Genentech, Inc. – Multiple Sclerosis
University of Washington – Triple-Negative Breast Cancer
Celldex Therapeutics – Metastatic gpNMB Expressing Triple Negative Breast Cancer
Eli Lilly and Company – Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
